Biofil Chemicals and Pharmaceuticals Limited reported a net profit of ₹278.60 crore for the financial year ended March 31, 2026, a significant increase from ₹55.78 crore in the previous year. The company's revenue from operations for FY26 stood at ₹2839.52 crore, down from ₹3340.22 crore in FY25. The Board of Directors approved the audited financial results for the fourth quarter and the financial year ended March 31, 2026, in a meeting held on May 30, 2026.

The statutory auditors, Maheshwari & Gupta, Chartered Accountants, issued an unmodified opinion on the standalone financial results. The audit was conducted in accordance with the Standards on Auditing specified under section 143(10) of the Companies Act, 2013. The company confirmed that the statement on impact of audit qualifications is not required as the auditors did not express any modified opinion or reservation.

For the quarter ended March 31, 2026, the company reported a net profit of ₹21.22 crore on a revenue from operations of ₹756.56 crore. Total income for the quarter was ₹767.41 crore, with total expenses amounting to ₹720.53 crore. The basic and diluted earnings per share for the quarter were ₹0.13, while for the full year, they stood at ₹1.71.

Financial Performance

The following table summarizes the key financial figures for the quarter and year ended March 31, 2026:

Segment Reporting

The company operates through two primary business segments: Pharma Division and Chemical Division. For the year ended March 31, 2026, the Pharma Division reported a revenue of ₹1,896.33 crore, while the Chemical Division contributed ₹943.19 crore. The Pharma Division recorded a segment profit before tax of ₹235.90 crore, whereas the Chemical Division reported a profit of ₹94.69 crore.

Operational Updates

The company noted that manufacturing operations were partially disrupted during the year due to renovation and upgradation work at the factory, necessitated by a revision in Schedule M of the Drug & Cosmetics Rules. This disruption resulted in a decline in turnover compared to the previous year. Additionally, the net profit for the year increased due to the disposal of an undertaking situated at Sanwer Road Industrial Area, Indore, to Formo Plast Private Limited.

The company submitted newspaper clippings of the publication of these audited financial results to the stock exchanges on June 1, 2026. The results were published in Free Press Mumbai & Indore (English) and Choutha Sansar (Hindi) on May 31, 2026.

biofil chemicals has scheduled a board meeting for May 30, 2026, to consider and approve the audited financial results for the fourth quarter and financial year ended March 31, 2026. The meeting will be held at the company's registered office located at B/12-B, Industrial Estate, Pologround, Indore-452015 (M.P.).

Agenda for the Meeting

The primary agenda item for the board meeting is the consideration and approval of the audited financial results for the quarter and year ending March 31, 2026. This includes the review of the Auditor's Report, the Statement of Assets and Liabilities, and the Cash Flow Statement. The board will also consider other routine matters with the permission of the chair.

Trading Window Update

In continuation of an earlier disclosure dated March 24, 2026, the company has informed the exchanges about the trading window closure. Pursuant to the Company's Code of Conduct to regulate, monitor, and report trading in the company's securities by Insiders, the trading window will open 48 hours after the declaration of the audited financial results. This applies to all designated persons, their immediate relatives, and all connected persons covered under the code.

Regulatory Compliance

The company confirmed that the information regarding the meeting and financial results will be submitted in XBRL mode, along with the submission in PDF mode, within the prescribed time limit. The intimation was sent to the Corporate Relationship Departments of both the National Stock Exchange of India Limited and BSE Limited.